Trial Profile
A Phase II Study of the Efficacy and Safety of Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer After Treatment With Pd-1 or Pd-L1 Inhibitors
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Jul 2023
Price :
$35
*
At a glance
- Drugs Axitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 26 Jun 2023 Status changed from active, no longer recruiting to completed.
- 16 Aug 2019 Primary endpoint (Progression free survival (PFS)) has not been met according to results published in the Lancet Oncology.
- 16 Aug 2019 Results assessing activity of dose titrated axitinib in patients with metastatic renal cell carcinoma, published in the Lancet Oncology.